



Ibrance[®] (palbociclib) – Expanded indication, label update

- On March 31, 2017, [Pfizer announced](#) the FDA approval of [Ibrance \(palbociclib\)](#) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) as initial endocrine based therapy in postmenopausal women.
 - Previously, Ibrance was only approved for use in combination with [Femara[®] \(letrozole\)](#) for this indication.
 - The FDA approval broadens the range of anti-hormonal therapy that may be administered with Ibrance.
- Ibrance is also approved for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with [Faslodex[®] \(fulvestrant\)](#) in women with disease progression following endocrine therapy.
- The expanded indication is based on data from a placebo-controlled clinical study ([PALOMA-2](#)) of 666 women with estrogen-receptor positive, HER2-negative breast cancer, who had not received prior treatment for advanced disease. The primary end point was progression-free survival (PFS).
 - The median PFS was 24.8 months in the Ibrance-Femara group vs. 14.5 months in the Ibrance-placebo group (hazard ratio for disease progression or death = 0.58; 95% CI, 0.46 to 0.72; p < 0.001).
- The recommended dose of Ibrance is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete 28 day cycle.
 - The recommended dose of an AI should be administered with Ibrance. Refer to the drug label for dosing information for the AI being used.
- Additionally, pulmonary embolism was removed from the *Warnings and Precautions* section of the Ibrance drug label.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.